This database contains 202 studies, archived under the term: "drug effects"
Click here to filter this large number of results.
Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial
Kamphuis, P. J. G. H.,
Verhey, F. R. J.,
Olde Rikkert, M. G. M.,
Twisk, J. W. R.,
Swinkels, S. H. N.,
Scheltens, P.
Objectives: To investigate the effect of a medical food (Souvenaid) on body mass index (BMI) and functional abilities in patients with mild Alzheimer’s disease (AD). DESIGN/SETTING/PARTICIPANTS/INTERVENTION /MEASUREMENTS: These analyses were performed on data from a 12-week, double-blind, randomized, controlled, multicenter, proof-of-concept study with a similarly designed and exploratory 12-week extension period. Patients with mild AD […]
Memantine in everyday clinical practice: a comparison of studies in Germany and Greece
Förstl, H.,
Stamouli, S. S.,
Janetzky, W.,
Galanopoulos, A.,
Karageorgiou, C.,
Tzanakaki, M.
Background/aims: Results from German and Greek non-interventional studies were compared to investigate possible differences concerning efficacy, tolerability and compliance between both countries.; Methods: In two open-label, multicentre, non-interventional studies, 4,305 patients with mild to severe Alzheimer’s disease (AD) were treated with daily doses of 20 mg memantine for 6 months. Efficacy was assessed using the […]
Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
de Yebenes, Justo Garcia,
Landwehrmeyer, Bernhard,
Squitieri, Ferdinando,
Reilmann, Ralf,
Rosser, Anne,
Barker, Roger A,
Saft, Carsten,
Magnet, Markus K.,
Sword, Alastair,
Rembratt, Åsa,
Tedroff, Joakim
Background: Huntington’s disease is a progressive neurodegenerative disorder, characterised by motor, cognitive, and behavioural deficits. Pridopidine belongs to a new class of compounds known as dopaminergic stabilisers, and results from a small phase 2 study in patients with Huntington’s disease suggested that this drug might improve voluntary motor function. We aimed to assess further the […]
A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s disease
Articus, K.,
Baier, M.,
Tracik, F.,
Kühn, F.,
Preuss, U. W.,
Kurz, A.
Background: Cholinesterase inhibitors form the mainstay of treatment for persons with mild-to-moderate Alzheimer’s disease (AD). The rivastigmine patch may increase compliance and the proportion of patients maintaining an efficacious dose compared with oral cholinesterase inhibitors.; Objective: To investigate the proportion of patients who reached and maintained the target rivastigmine patch dose compared with the target […]
Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment
Yamada, Shizuru,
Akishita, Masahiro,
Fukai, Shiho,
Ogawa, Sumito,
Yamaguchi, Kiyoshi,
Matsuyama, Jun,
Kozaki, Koichi,
Toba, Kenji,
Ouchi, Yasuyoshi
Aim: There is little evidence that dehydroepiandrosterone (DHEA) has beneficial effects on physical and psychological functions in older women. We investigated the effect of DHEA supplementation on cognitive function and ADL in older women with cognitive impairment.; Methods: A total of 27 women aged 65-90 years (mean ± standard deviation, 83 ± 6) with mild […]
Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone
Valen-Sendstad, Arnhild,
Engedal, Knut,
Stray-Pedersen, Babill,
Strobel, Carsten,
Barnett, Liv,
Meyer, Nicolay,
Nurminemi, Minna
Objective: To elucidate the effects of low-dose 17beta-estradiol and norethisterone (hormone therapy [HT]) versus placebo in women with Alzheimer Disease (AD) on cognition, depressive symptoms, and activities of daily living.; Design: A 12-month randomized, double-blind, placebo-controlled study, stratified by apolipoprotein E (ApoE) genotype (with versus without the epsilon4 allele), duration of education (< or =9 […]
Efficacy of rivastigmine on executive function in patients with Parkinson’s disease dementia
Background and Objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective was to investigate the effects of rivastigmine capsules versus placebo on EF in PDD, focusing on secondary outcome measures […]
Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size
Román, Gustavo C.,
Salloway, Stephen,
Black, Sandra E.,
Royall, Donald R.,
DeCarli, Charles,
Weiner, Michael W.,
Moline, Margaret,
Kumar, Dinesh,
Schindler, Rachel,
Posner, Holly
Background and Purpose: We sought to assess the efficacy and safety of donepezil in patients with vascular dementia (VaD) fulfilling National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences criteria.; Methods: This international, multicenter, 24-week trial was conducted from March 2003 to August 2005. Patients (N=974; mean age, 73.0 […]